Published in J Virol on April 30, 2008
The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol (2009) 2.15
T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A (2011) 2.12
The Myeloid LSECtin Is a DAP12-Coupled Receptor That Is Crucial for Inflammatory Response Induced by Ebola Virus Glycoprotein. PLoS Pathog (2016) 1.39
Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc Natl Acad Sci U S A (2009) 1.26
Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci U S A (2010) 1.14
Characterization of Chikungunya pseudotyped viruses: Identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology (2009) 1.09
Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. J Virol (2012) 1.08
Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol (2015) 1.07
Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res (2014) 0.94
The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res (2012) 0.92
Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol (2013) 0.86
Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One (2013) 0.81
The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies. J Virol (2016) 0.76
The Roles of Histidines and Charged Residues as Potential Triggers of a Conformational Change in the Fusion Loop of Ebola Virus Glycoprotein. PLoS One (2016) 0.75
Molecular pathogenesis of viral hemorrhagic fever. Semin Immunopathol (2017) 0.75
Structure of the Ebola virus envelope protein MPER/TM domain and its interaction with the fusion loop explains their fusion activity. Proc Natl Acad Sci U S A (2017) 0.75
Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol (1977) 41.93
A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A (1997) 6.86
Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol (1998) 5.16
Host-range mutants of adenovirus type 5 defective for growth in HeLa cells. Virology (1977) 4.40
Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol (2006) 4.24
Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science (1998) 4.24
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
Integrins, oncogenes, and anchorage independence. J Cell Biol (1997) 2.86
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem (2006) 2.56
Comprehensive analysis of ebola virus GP1 in viral entry. J Virol (2005) 2.56
Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology (2000) 2.33
Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol (2006) 2.24
Arf6 and microtubules in adhesion-dependent trafficking of lipid rafts. Nat Cell Biol (2007) 2.23
Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol (2001) 2.13
Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol (2007) 1.93
Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med (2006) 1.92
Infection and activation of monocytes by Marburg and Ebola viruses. J Virol (2001) 1.90
A comparison of differences in the gene expression profiles of phorbol 12-myristate 13-acetate differentiated THP-1 cells and human monocyte-derived macrophage. J Atheroscler Thromb (2004) 1.34
Filovirus contamination of cell cultures. Dev Biol Stand (1992) 1.17
Identification of the promoter of the myelomonocytic leukocyte integrin CD11b. Proc Natl Acad Sci U S A (1992) 1.13
Comparison of retinoic acid and phorbol myristate acetate as inducers of monocytic differentiation. Int J Cancer (1994) 0.89
[The effect of translation inhibitor cycloheximide on expression of mammalian genes]. Biokhimiia (1990) 0.80
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol (2008) 5.26
Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc Natl Acad Sci U S A (2006) 3.25
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A (2005) 3.18
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol (2006) 2.95
Comparative analysis of bat genomes provides insight into the evolution of flight and immunity. Science (2012) 2.29
The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol (2009) 2.15
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog (2009) 2.09
Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A (2008) 2.08
Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood (2003) 2.00
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol (2006) 2.00
Regulation of lamellipodial persistence, adhesion turnover, and motility in macrophages by focal adhesion kinase. J Cell Biol (2007) 1.93
Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol (2005) 1.89
Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods (2003) 1.87
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol (2006) 1.87
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol (2002) 1.69
Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat. J Infect Dis (2007) 1.68
The avian retrovirus avian sarcoma/leukosis virus subtype A reaches the lipid mixing stage of fusion at neutral pH. J Virol (2003) 1.63
Sequential roles of receptor binding and low pH in forming prehairpin and hairpin conformations of a retroviral envelope glycoprotein. J Virol (2004) 1.62
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol (2007) 1.61
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther (2011) 1.61
Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One (2010) 1.54
Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. J Biol Chem (2002) 1.54
Antibodies to Nipah or Nipah-like viruses in bats, China. Emerg Infect Dis (2008) 1.53
Fusion peptide of influenza hemagglutinin requires a fixed angle boomerang structure for activity. J Biol Chem (2005) 1.51
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A (2007) 1.50
Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis (2008) 1.48
Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol (2011) 1.46
Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate. J Virol (2004) 1.44
A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine (2008) 1.41
Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding. J Virol (2008) 1.40
A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine (2011) 1.39
Leash in the groove mechanism of membrane fusion. Nat Struct Biol (2003) 1.36
A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med (2011) 1.35
Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res (2007) 1.33
Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm (2005) 1.33
Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein. Virol J (2007) 1.30
Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One (2013) 1.29
Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc Natl Acad Sci U S A (2009) 1.26
Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. J Biol Chem (2003) 1.24
A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol (2010) 1.21
Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. Virol J (2005) 1.21
Functional studies of host-specific ephrin-B ligands as Henipavirus receptors. Virology (2007) 1.21
Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proc Natl Acad Sci U S A (2011) 1.20
A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med (2012) 1.20
Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell (2005) 1.20
Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods (2006) 1.19
Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol (2010) 1.17
Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis (2014) 1.16
Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci U S A (2010) 1.14
Animal challenge models of henipavirus infection and pathogenesis. Curr Top Microbiol Immunol (2012) 1.11
A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Res (2008) 1.10
Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Virol (2009) 1.09
A new player in the puzzle of filovirus entry. Nat Rev Microbiol (2012) 1.08
Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses. Immunol Cell Biol (2005) 1.06
The YPLGVG sequence of the Nipah virus matrix protein is required for budding. Virol J (2008) 1.05
FAK regulates intestinal epithelial cell survival and proliferation during mucosal wound healing. PLoS One (2011) 1.04
Helicobacter pylori induces interleukin-8 secretion by Toll-like receptor 2- and Toll-like receptor 5-dependent and -independent pathways. Infect Immun (2005) 1.03
Novel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complex. J Virol (2002) 1.02
Antibodies to henipavirus or henipa-like viruses in domestic pigs in Ghana, West Africa. PLoS One (2011) 1.02
Hendra and Nipah viruses: pathogenesis and therapeutics. Curr Mol Med (2005) 1.02
HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. AIDS (2004) 1.01
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol (2005) 1.01
New insights into the spring-loaded conformational change of influenza virus hemagglutinin. J Virol (2002) 1.01
Conserved eukaryotic fusogens can fuse viral envelopes to cells. Science (2011) 1.01
The cysteine-rich domain regulates ADAM protease function in vivo. J Cell Biol (2002) 1.00
Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors. Methods Mol Biol (2004) 0.99
Cysteines flanking the internal fusion peptide are required for the avian sarcoma/leukosis virus glycoprotein to mediate the lipid mixing stage of fusion with high efficiency. J Virol (2008) 0.99
Henipavirus neutralising antibodies in an isolated island population of African fruit bats. PLoS One (2012) 0.98
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther (2009) 0.98
A spatio-temporal analysis of matrix protein and nucleocapsid trafficking during vesicular stomatitis virus uncoating. PLoS Pathog (2010) 0.97
Structural requirements for the inhibitory action of the CD9 large extracellular domain in sperm/oocyte binding and fusion. Biochem Biophys Res Commun (2003) 0.97
Glycoprotein-dependent acidification of vesicular stomatitis virus enhances release of matrix protein. J Virol (2009) 0.97